


Fiboflapon sodium

Chemical Properties

CAS No. :	1196070-26-4
Formula:	C ₃₈ H ₄₃ N ₃ NaO ₄ S
Molecular Weight:	660.83
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Fiboflapon sodium (GSK2190915) is an orally bioavailable 5-lipoxygenase-activating protein (FLAP) inhibitor with a potency of 2.9 nM in FLAP binding, an IC ₅₀ of 76 nM for inhibition of LTB ₄ in human blood.
Targets(IC ₅₀)	LTR,FLAP,Leukotriene Receptor
In vitro	In vivo studies revealed that Fiboflapon (AM803) effectively inhibits the production of LTB ₄ and cysteinyl leukotriene (CysLT) in rat lungs challenged with calcium-ionophore, showing ED ₅₀ values of 0.12 mg/kg and 0.37 mg/kg, respectively. Following a single oral dose of 3 mg/kg, inhibition levels 16 hours post-administration were 86% for LTB ₄ and 41% for CysLTs. In scenarios of acute inflammation, Fiboflapon (AM803) demonstrated a dose-dependent reduction in LTB ₄ , CysLTs, plasma protein extravasation, and neutrophil influx following peritoneal zymosan injection. Furthermore, AM803 significantly prolonged survival in mice after a lethal dose of platelet-activating factor (PAF) intravenously. Fiboflapon (AM803) has shown excellent preclinical toxicology and pharmacokinetics in rats and dogs, alongside a remarkable pharmacodynamic extension in a rodent bronchoalveolar lavage (BAL) model. Oral administration at 1 mg/kg led to a sustained inhibition of LTB ₄ biosynthesis in ex vivo ionophore-challenged whole blood, with over 90% inhibition lasting up to 12 hours and an EC ₅₀ of approximately 7 nM.

Solubility Information

Solubility	DMSO: 32 mg/mL (48.42 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5132 mL	7.5662 mL	15.1325 mL
5 mM	0.3026 mL	1.5132 mL	3.0265 mL
10 mM	0.1513 mL	0.7566 mL	1.5132 mL
50 mM	0.0303 mL	0.1513 mL	0.3026 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Stock NS, et al. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor. *J Med Chem.* 2011 Dec 8;54(23):8013-29.

Lorrain DS, et al. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. *Eur J Pharmacol.* 2010 Aug 25;640(1-3):211-8.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481